Isaac Ro
Isaac Ro is a Partner at Catalio Capital Management where he has led multiple venture and private credit investments in breakthrough life science companies. He currently serves on the boards of Pink Dx and PrognomiQ. Previously, he was Executive Chairman of Haystack Oncology and led the sale of the company to Quest Diagnostics in 2023. He also served as Chief Financial Officer of Sema4 (NASDAQ: WGS) where he took the company public in 2021 and led the acquisition of GeneDx. He previously served as the Chief Financial Officer of Thrive Earlier Detection where he led the launch and subsequent sale of the company to Exact Sciences in 2020. From 2010 to 2019, Isaac led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs. Prior to Goldman Sachs, he held the same role at Leerink Partners. Isaac earned his B.A. in History and was Pre-Med at Middlebury College.